Neurofibrosarcoma - Pipeline Insight, 2024

This Neurofibrosarcoma - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Neurofibrosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Neurofibrosarcoma Understanding

Neurofibrosarcoma: Overview

Neurofibromatosis (NF) is a progressive and autosomal dominant inherited disorder of the nervous system which causes tumors to form on the nerves anywhere in the body, at any time. Neurofibromatosis skin lesions are typically flat, pigmented patches but occasionally are elevated flesh-colored bumps. NF1 and NF2 are inherited in an autosomal dominant pattern, with an approximately 50% rate of de novo mutations in each. The genetic mechanism of SWN is more complex and the rate of new mutations probably lies between 50% and 80%. Schwannomatosis (SWN) is the rarest form of these three conditions and is genetically and clinically distinct from NF1 and NF2. In most cases, symptoms of NF1 are relatively mild, allowing patients to live normal and productive lives. However, the disorder can also be debilitating and, in some cases, life-threatening.

Neurofibrosarcoma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neurofibrosarcoma pipeline landscape is provided which includes the disease overview and Neurofibrosarcoma treatment guidelines. The assessment part of the report embraces, in depth Neurofibrosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neurofibrosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Neurofibrosarcoma. The therapies under development are focused on novel approaches to treat/improve Neurofibrosarcoma.

Neurofibrosarcoma Emerging Drugs

NFX-179: NFlection Therapeutics
NFX-179 is an investigational mitogen-activated protein kinase kinase (MEK) inhibitor. NFX-179 is a soft (metabolically labile) drug, which, when formulated as NFX-179 Gel for topical application, is designed to concentrate at the dermal site of action but degrade in systemic circulation, thereby significantly reducing side effects compared to systemically available MEK inhibitors.

Sirolimus: Nobelpharma
Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus: FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target of Rapamycin (m TOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cellcycle

Neurofibrosarcoma: Therapeutic Assessment

This segment of the report provides insights about the Neurofibrosarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Neurofibrosarcoma

There are approx. 15+ key companies which are developing the therapies Neurofibrosarcoma. The companies which have their Neurofibrosarcoma drug candidates in the most advanced stage, i.e phase III include Nobelpharma

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Neurofibrosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neurofibrosarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neurofibrosarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neurofibrosarcoma drugs.

Neurofibrosarcoma Report Insights

• Neurofibrosarcoma Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Neurofibrosarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Neurofibrosarcoma drugs?
• How many Neurofibrosarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neurofibrosarcoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Neurofibrosarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Neurofibrosarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Daiichi Sankyo
• Chia Tai Tianqing Pharmaceutical Group
• Mirati Therapeutics
• Astex Pharmaceuticals
• Ascentage Pharma Group
• Apexigen
• Nobelpharma
• Pfizer
• Spring WorksTherapeutics
• NFlection Therapeutics

Key Products

• PLX3397
• AL2846
• MRTX1719
• ASTX727
• APG-115
• APX005M
• Sirolimus
• Tanezumab
• Mirdametinib
• NFX-179

This product will be delivered within 1-3 business days.